Enliven Therapeutics has decided against taking its phase 1-stage solid tumor drug into further development next year in ...

England’s drug approval body has resisted pressure from pharmaceutical companies to loosen its process for recommending drugs and is pressing instead for the NHS to speed up the rollout of approved ...

Daiichi Sankyo has been ordered to pay an 8% royalty rate on sales of AstraZeneca-partnered breast and gastric cancer therapy Enhertu (trastuzumab deruxtecan) after Seagen won a lawsuit claiming ...

Positive results from the DESTINY-Breast11 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), when ...

AstraZeneca and Daiichi Sankyo's Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage breast cancer for the first time.